Hafiz Zafar Ahmed Mahmood, MD
Nephrology · Huntsville, ALNPI 1376098657
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,350 of the $2,665 with a category attached, or 88.2%. It is spread thinly across 22 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $790 and has fallen 50.0% since, to $395 in 2025.
Across 121 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$314
- Amgen$259
- Otsuka America Pharmaceutical, Inc.$220
- OPKO Pharmaceuticals, LLC$216
- AstraZeneca$209
- ANI Pharmaceuticals, Inc.$170
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,35088%
- Education$31612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 18 | $314 |
| Amgen | 11 | $259 |
| Otsuka America Pharmaceutical, Inc. | 10 | $220 |
| OPKO Pharmaceuticals, LLC | 14 | $216 |
| AstraZeneca | 9 | $209 |
| ANI Pharmaceuticals, Inc. | 6 | $170 |
| Calliditas Therapeutics US Inc. | 6 | $157 |
| Bayer | 6 | $138 |
| Akebia Therapeutics Inc | 1 | $123 |
| Travere Therapeutics, Inc. | 4 | $122 |
| Fresenius USA Marketing, Inc. | 5 | $121 |
| Mallinckrodt Hospital Products Inc. | 6 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Novo Nordisk | 4 | $72 |
| Novartis | 3 | $69 |
| Aurinia Pharma U.S., Inc. | 3 | $64 |
| Daiichi Sankyo Inc. | 3 | $57 |
| GSK | 3 | $51 |
| Apellis Pharmaceuticals, Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vafseo$123
How this compares
$2,665 in reported general payments places this provider in the 55th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Furosemide | 13 | $92 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Huntsville
- Michael QuadriniHuntsville$323K
- James SmelserHuntsville$20K
- Carlo CastilloHuntsville$7K
- Todd BroomeHuntsville$7K
- Heather HaleyHuntsville$6K
- Saad RahmanHuntsville$6K
- Roger CoomerHuntsville$6K
- David BainsHuntsville$5K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.